Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

Rhea-AI Summary

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced it will release its fourth quarter and full year 2021 financial results on March 2, 2022, before market open. A conference call will follow at 8:30 a.m. Eastern Time on the same day, accessible via the Investor Relations section of the Company’s website. Investors can dial (844) 200-6205 in the U.S. or (929) 526-1599 internationally to join the call. A replay will be available for seven days after the call. Amneal is a fully-integrated essential medicines company, focusing on generics and specialty pharmaceuticals.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2022.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

To access the call through a conference line, dial (844) 200-6205 (in the U.S.) or (929) 526-1599 (international callers). The access code for the call is 086998.

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 311554.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220204005021/en/

Anthony DiMeo

Senior Director, Investor Relations

Anthony.DiMeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.

FAQ

When will Amneal Pharmaceuticals release its Q4 and full year 2021 financial results?

Amneal Pharmaceuticals will release its Q4 and full year 2021 financial results on March 2, 2022.

What time is the Amneal Pharmaceuticals conference call on March 2, 2022?

The conference call for Amneal Pharmaceuticals will take place at 8:30 a.m. Eastern Time on March 2, 2022.

How can I access the Amneal Pharmaceuticals earnings call?

To access the Amneal Pharmaceuticals earnings call, dial (844) 200-6205 in the U.S. or (929) 526-1599 internationally, with access code 086998.

Is there a replay available for the Amneal Pharmaceuticals conference call?

Yes, a replay of the Amneal Pharmaceuticals conference call will be available for seven days after the call.

What products does Amneal Pharmaceuticals focus on?

Amneal Pharmaceuticals develops generic and specialty pharmaceuticals, with a diverse portfolio including injectables and biosimilars.